Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
N4 Pharma ( (GB:N4P) ) just unveiled an announcement.
N4 Pharma has achieved a significant milestone in its collaboration with SRI by successfully targeting RNA delivery to non-small cell lung cancer cells using its Nuvec® platform. This advancement demonstrates the potential of Nuvec® as a differentiated delivery system for RNA therapeutics, particularly in oncology, and positions the company to meet the growing demand for targeted therapies, enhancing its market positioning and potential for strategic partnerships.
More about N4 Pharma
N4 Pharma plc is a UK-based biotechnology company focused on developing Nuvec®, a proprietary gene delivery system designed to enable advanced therapies for cancer and other diseases. The company aims to address challenges in the RNA therapeutics market, which is projected to grow significantly, by providing targeted and efficient delivery solutions.
Average Trading Volume: 1,350,989
Technical Sentiment Signal: Sell
Current Market Cap: £7.62M
See more data about N4P stock on TipRanks’ Stock Analysis page.